

Anita K Gandhi

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/244943/publications.pdf>

Version: 2024-02-01

21
papers

2,220
citations

567281

15
h-index

713466

21
g-index

21
all docs

21
docs citations

21
times ranked

3020
citing authors

#	ARTICLE	IF	CITATIONS
1	Lenalidomide induces ubiquitination and degradation of CK1 α in del(5q) MDS. <i>Nature</i> , 2015, 523, 183-188.	27.8	648
2	Immunomodulatory agents lenalidomide and pomalidomide co-stimulate T cells by inducing degradation of T cell repressors IKAROS and AIOLOS via modulation of the E3 ubiquitin ligase complex CRL4 ^{CRBN} . <i>British Journal of Haematology</i> , 2014, 164, 811-821.	2.5	505
3	Pomalidomide and Lenalidomide Induce p21WAF-1 Expression in Both Lymphoma and Multiple Myeloma through a LSD1-Mediated Epigenetic Mechanism. <i>Cancer Research</i> , 2009, 69, 7347-7356.	0.9	167
4	Enhancement of Cytokine Production and AP-1 Transcriptional Activity in T Cells by Thalidomide-Related Immunomodulatory Drugs. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2003, 305, 1222-1232.	2.5	165
5	CC-122, a pleiotropic pathway modifier, mimics an interferon response and has antitumor activity in DLBCL. <i>Blood</i> , 2015, 126, 779-789.	1.4	148
6	Lenalidomide inhibits proliferation of Namalwa CSN.70 cells and interferes with Gab1 phosphorylation and adaptor protein complex assembly. <i>Leukemia Research</i> , 2006, 30, 849-858.	0.8	103
7	Measuring cereblon as a biomarker of response or resistance to lenalidomide and pomalidomide requires use of standardized reagents and understanding of gene complexity. <i>British Journal of Haematology</i> , 2014, 164, 233-244.	2.5	93
8	A First-in-Human Study of Novel Cereblon Modulator Avadomide (CC-122) in Advanced Malignancies. <i>Clinical Cancer Research</i> , 2019, 25, 90-98.	7.0	73
9	Avadomide monotherapy in relapsed/refractory DLBCL: safety, efficacy, and a predictive gene classifier. <i>Blood</i> , 2020, 135, 996-1007.	1.4	49
10	Pomalidomide in combination with dexamethasone results in synergistic anti-tumour responses in pre-clinical models of lenalidomide-resistant multiple myeloma. <i>British Journal of Haematology</i> , 2016, 172, 889-901.	2.5	47
11	Triggering interferon signaling in T cells with avadomide sensitizes CLL to anti-PD-L1/PD-1 immunotherapy. <i>Blood</i> , 2021, 137, 216-231.	1.4	40
12	Activity of lenalidomide in mantle cell lymphoma can be explained by NK cell-mediated cytotoxicity. <i>British Journal of Haematology</i> , 2017, 179, 399-409.	2.5	39
13	Combination lenalidomide-rituximab immunotherapy activates anti-tumour immunity and induces tumour cell death by complementary mechanisms of action in follicular lymphoma. <i>British Journal of Haematology</i> , 2019, 185, 240-253.	2.5	39
14	Immunomodulatory Effects in a Phase II Study of Lenalidomide Combined with Cetuximab in Refractory KRAS-Mutant Metastatic Colorectal Cancer Patients. <i>PLoS ONE</i> , 2013, 8, e80437.	2.5	28
15	Targeting of inflammatory pathways with R2CHOP in high-risk DLBCL. <i>Leukemia</i> , 2021, 35, 522-533.	7.2	28
16	A Dual Color Immunohistochemistry Assay for Measurement of Cereblon in Multiple Myeloma Patient Samples. <i>Applied Immunohistochemistry and Molecular Morphology</i> , 2016, 24, 695-702.	1.2	13
17	Leveraging Gene Expression Subgroups to Classify DLBCL Patients and Enrich for Clinical Benefit to a Novel Agent. <i>Blood</i> , 2020, 135, 1008-1018.	1.4	12
18	CC-122 Has Robust Anti-Proliferative Activity in a Primary Chronic Lymphocytic Leukemia (CLL) Co-Culture Model and Is Superior to Lenalidomide. <i>Blood</i> , 2014, 124, 4682-4682.	1.4	7

#	ARTICLE	IF	CITATIONS
19	CC-122 Dosing on a Novel Intermittent Schedule Mitigates Neutropenia and Maintains Clinical Activity in Subjects with Relapsed or Refractory Diffuse Large B Cell Lymphoma. <i>Blood</i> , 2015, 126, 1494-1494.	1.4	7
20	A First In Human Dose Escalation Study Of CC-122, A First-In-Class Pleiotropic Pathway Modulator (PPM) Compound In Subjects With Relapsed Or Refractory Solid Tumors, Multiple Myeloma and Non-Hodgkin's Lymphoma. <i>Blood</i> , 2013, 122, 2905-2905.	1.4	5
21	Phase Ib study of combinations of avadomide (CC-122), CC-223, CC-292, and rituximab in patients with relapsed/refractory diffuse large B-cell lymphoma. <i>EJHaem</i> , 2022, 3, 139-153.	1.0	4